Skip to main content
Premium Trial:

Request an Annual Quote

Oppenheimer Initiates Coverage of Fulgent Genetics With Outperform Rating

NEW YORK – Oppenheimer on Wednesday initiated coverage of Fulgent Genetics with an Outperform rating and a price target on its shares of $75.

Fulgent is "the world's most highly leveraged publicly traded company to PCR testing for the detection of COVID-19," Oppenheimer Analyst Kevin DeGeeter wrote in a research note sent to investors and noted that the firm benefited from early adopter positioning and an expanded menu of testing options. He added that the stock provided an opportunity to gain market share as the pandemic testing market matures as well as a hedge against upcoming data disclosures by COVID-19 vaccine programs.

Oppenheimer's forecast for Fulgent's Fiscal Year 2021 revenues of $235.6 million is above the consensus Wall Street estimate of $173.5 million.

BTIG initiated coverage of Fulgent in May with a Buy rating; PiperSandler also covers the stock. Earlier this month, both investment banks increased their price targets for shares of Fulgent to $35 and $68, respectively.

In Thursday morning trading on the Nasdaq, shares of Fulgent jumped 12 percent to $49.15.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.